Celgene Corp. Given New $176.00 Price Target at Guggenheim (CELG)
Research analysts at Guggenheim upped their price target on shares of Celgene Corp. (NASDAQ:CELG) from $152.00 to $176.00 in a report released on Thursday, StockRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Guggenheim’s target price points to a potential upside of 13.01% from the stock’s previous close.
CELG has been the subject of a number of other recent research reports. Analysts at Deutsche Bank raised their price target on shares of Celgene Corp. from $162.00 to $170.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Separately, analysts at RBC Capital raised their price target on shares of Celgene Corp. from $150.00 to $170.00 in a research note to investors on Wednesday, October 9th. They now have an “outperform” rating on the stock. Finally, analysts at Bank of America Corp. raised their price target on shares of Celgene Corp. from $164.00 to $179.00 in a research note to investors on Tuesday, October 8th. They now have a “buy” rating on the stock. Five investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $153.78.
Celgene Corp. (NASDAQ:CELG) traded down 1.41% during mid-day trading on Thursday, hitting $155.74. The stock had a trading volume of 3,234,185 shares. Celgene Corp. has a 1-year low of $70.42 and a 1-year high of $151.00. The stock’s 50-day moving average is $142.3 and its 200-day moving average is $125.4. The company has a market cap of $64.052 billion and a P/E ratio of 44.17.
Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 24th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the previous year, the company posted $1.29 earnings per share. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. Analysts expect that Celgene Corp. will post $5.99 EPS for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.